

mAbs, Nibs und Co. bei entzündlichen rheumatischen Erkrankungen

Elisabeth Deibel, Lukas Wildi

Referenzen

1. Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis* 2020;0:1–15.
2. Sandborn WJ, et al. Etanercept for Active Crohn's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. *Gastroenterology* 2001;121:1088 –1094
3. Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. *Ann Rheum Dis* 2018; 77:228.
4. Dominique B, et al. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. *The New England Journal of Medicine* 373;26
5. Coates L C et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. *Arthritis & Rheumatology* Vol. 68, No. 5, May 2016, pp 1060–1071
6. Orbai A, et al. Systematic Review of Treatment Effectiveness and Outcome Measures for Enthesitis in Psoriatic Arthritis. *The Journal of Rheumatology* 2014;41:2290-2294
7. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. *J Med Virol.* 2020;1-5
8. Chi Zhang MD , Zhao Wu PhD , Jia-Wen Li MD , Hong Zhao PhD , Gui-Qiang Wang MD , The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality, *International Journal of Antimicrobial Agents* (2020), doi
9. Stone JH, et al. Trial of Tocilizumab in Giant-Cell Arteritis. *N Engl J Med* 377;4
10. Khanna D, et al. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSSciate). *Ann Rheum Dis* 2018;77:212–220
11. Yun H, et al. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare, *Arthritis & Rheumatology* Vol. 68, No. 1, January 2016, pp 56–66
12. Pesu M, et al. Therapeutic targets of Janus Kinases, *Immunol Rev.* 2008 Jun;223:132-42.
13. Aaltonen KJ et al. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. *PLoS One.* 2012;7(1):e30275.
14. Curtis JR et al. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. *Ann Rheum Dis.* 2016 Oct;75(10):1843-7.
15. Strand V et al. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review. *BioDrugs.* 2017 Aug;31(4):299-316.

16. Scott Algood HM, Ling Lin P, and Flynn JL. Tumor Necrosis Factor and Chemokine Interactions in the Formation and Maintenance of Granulomas in Tuberculosis. *Clin Infect Dis*. 2005 Aug 1;41 Suppl 3:S189-93.
17. Blauvelt A. Safety of secukinumab in the treatment of psoriasis. *Expert Opinion on Drug Safety*, 15:10, 1413-1420.
18. Shivaji UN et al. Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease. *Aliment Pharmacol Ther*. 2019;49:664–680.